Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development?
The development of malaria blood-stage vaccines is gathering momentum: there are several new funding initiatives, one multiantigen formulation is currently being tested and at least one other blood-stage vaccine is expected to begin trials in 2001. However, there is no consensus over the best way to select which form of an antigen to take into clinical testing. There is thus a danger that less-effective vaccines might be tested in the field in the order of their availability, rather than merit. Here, we argue that first proving efficacy in the New World monkey challenge model would accelerate development.
Stowers
A W
AW
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infections Diseases, National Institutes of Health, Rockville, MD 20852, USA. astowers@niaid.nih.gov
Miller
L H
LH
D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D001029:Aotus trivirgatus; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004912:Erythrocytes / Q000469:parasitology*; D006801:Humans; D008018:Life Cycle Stages; D008288:Malaria / Q000517:prevention & control*; D017780:Malaria Vaccines; D010963:Plasmodium falciparum / Q000276:immunology*
D000953:Antigens, Protozoan; D017780:Malaria Vaccines